Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread?
Pharmacoeconomics
.
2017 Nov;35(11):1111-1112.
doi: 10.1007/s40273-017-0561-x.
Authors
Jonathan Karnon
1
,
Hossein Hajiali Afzali
2
Affiliations
1
University of Adelaide, Adelaide, SA, Australia. jonathan.karnon@adelaide.edu.au.
2
University of Adelaide, Adelaide, SA, Australia.
PMID:
28831709
DOI:
10.1007/s40273-017-0561-x
No abstract available
Publication types
Editorial
Comment
MeSH terms
Cost-Benefit Analysis
Decision Making*
Models, Economic*
Uncertainty